JP2011500851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500851A5 JP2011500851A5 JP2010531299A JP2010531299A JP2011500851A5 JP 2011500851 A5 JP2011500851 A5 JP 2011500851A5 JP 2010531299 A JP2010531299 A JP 2010531299A JP 2010531299 A JP2010531299 A JP 2010531299A JP 2011500851 A5 JP2011500851 A5 JP 2011500851A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- active agent
- dry powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000013543 active substance Substances 0.000 claims 7
- 239000005556 hormone Substances 0.000 claims 6
- 229940088597 hormone Drugs 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 230000002124 endocrine Effects 0.000 claims 4
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 4
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- -1 glutaryl Chemical group 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 2
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98236807P | 2007-10-24 | 2007-10-24 | |
| US60/982,368 | 2007-10-24 | ||
| US98562007P | 2007-11-05 | 2007-11-05 | |
| US60/985,620 | 2007-11-05 | ||
| US2227408P | 2008-01-18 | 2008-01-18 | |
| US61/022,274 | 2008-01-18 | ||
| US3374008P | 2008-03-04 | 2008-03-04 | |
| US61/033,740 | 2008-03-04 | ||
| US5212708P | 2008-05-09 | 2008-05-09 | |
| US61/052,127 | 2008-05-09 | ||
| US9482308P | 2008-09-05 | 2008-09-05 | |
| US61/094,823 | 2008-09-05 | ||
| PCT/US2008/081221 WO2009055742A2 (en) | 2007-10-24 | 2008-10-24 | Delivery of active agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015145109A Division JP2015227357A (ja) | 2007-10-24 | 2015-07-22 | 活性薬剤の送達方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500851A JP2011500851A (ja) | 2011-01-06 |
| JP2011500851A5 true JP2011500851A5 (enExample) | 2011-12-08 |
| JP5813323B2 JP5813323B2 (ja) | 2015-11-17 |
Family
ID=40545981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531299A Active JP5813323B2 (ja) | 2007-10-24 | 2008-10-24 | 活性薬剤の送達方法 |
| JP2015145109A Pending JP2015227357A (ja) | 2007-10-24 | 2015-07-22 | 活性薬剤の送達方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015145109A Pending JP2015227357A (ja) | 2007-10-24 | 2015-07-22 | 活性薬剤の送達方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US8372804B2 (enExample) |
| EP (1) | EP2214647A2 (enExample) |
| JP (2) | JP5813323B2 (enExample) |
| KR (2) | KR20100090692A (enExample) |
| CN (1) | CN101969928B (enExample) |
| AU (1) | AU2008316636B2 (enExample) |
| BR (1) | BRPI0818874A2 (enExample) |
| CA (1) | CA2703234C (enExample) |
| MX (1) | MX2010004508A (enExample) |
| RU (2) | RU2467741C2 (enExample) |
| WO (1) | WO2009055742A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1808438T3 (da) | 1999-06-29 | 2014-10-27 | Mannkind Corp | Rensning og stabilisering af peptid og proteiner i lægemidler |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| AU2003220125B2 (en) | 2002-03-20 | 2006-06-15 | Mannkind Corporation | Inhalation apparatus |
| US8921311B2 (en) | 2003-08-01 | 2014-12-30 | Mannkind Corporation | Method for treating hyperglycemia |
| PL1786784T3 (pl) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Kataliza syntezy diketopiperazyn |
| EP2314298B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
| AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| DK1986679T3 (da) | 2006-02-22 | 2017-11-20 | Mannkind Corp | Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof |
| AU2008316634B2 (en) * | 2007-10-24 | 2014-02-27 | Mannkind Corporation | Method of preventing adverse effects by GLP-1 |
| WO2009055742A2 (en) * | 2007-10-24 | 2009-04-30 | Mannkind Corporation | Delivery of active agents |
| US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CN103252007B (zh) | 2008-06-13 | 2016-06-22 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| JP5479465B2 (ja) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | 吸入努力をリアルタイムにプロファイルする対話式機器および方法 |
| TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US20100169260A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
| US9750903B2 (en) | 2008-12-30 | 2017-09-05 | Gearbox, Llc | Method for administering an inhalable compound |
| CA2749099A1 (en) * | 2009-01-08 | 2010-07-15 | Mannkind Corporation | Method for treating hyperglycemia with glp-1 |
| EP2676695A3 (en) | 2009-03-11 | 2017-03-01 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| KR101875969B1 (ko) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
| WO2010144785A2 (en) * | 2009-06-12 | 2010-12-16 | Mannkind Corporation | Diketopiperazine microparticles with defined isomer contents |
| AU2010313173B2 (en) | 2009-11-02 | 2015-02-12 | Mannkind Corporation | Apparatus and method for cryogranulating a pharmaceutical composition |
| CA2979182C (en) * | 2009-11-02 | 2021-03-02 | Mannkind Corporation | Reactor for producing pharmaceutical particles in a precipitation process |
| AU2015201885B2 (en) * | 2009-11-02 | 2017-04-20 | Mannkind Corporation | Apparatus and method for cryogranulating a pharmaceutical composition |
| WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| US8790704B2 (en) * | 2010-06-10 | 2014-07-29 | Monosol Rx, Llc | Combination peptide-nanoparticles and delivery systems incorporating same |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| AU2015249177B2 (en) * | 2010-11-09 | 2017-08-03 | Mannkind Corporation | Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
| ES2732818T3 (es) * | 2010-11-09 | 2019-11-26 | Mannkind Corp | Composición que comprende un agonista de receptores de serotonina y una dicetopiperazina para tratar migrañas |
| CN105667994B (zh) | 2011-04-01 | 2018-04-06 | 曼金德公司 | 用于药物药盒的泡罩包装 |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| WO2013063160A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
| SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
| CA2882958A1 (en) * | 2012-08-29 | 2014-03-06 | Mannkind Corporation | Method and composition for treating hyperglycemia |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| EP2970149B1 (en) * | 2013-03-15 | 2019-08-21 | MannKind Corporation | Microcrystalline diketopiperazine compositions and methods |
| CN105451716A (zh) * | 2013-07-18 | 2016-03-30 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
| WO2015021064A1 (en) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Insufflation apparatus and methods |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| US10307464B2 (en) * | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| WO2017132601A1 (en) * | 2016-01-29 | 2017-08-03 | Mannkind Corporation | Dry powder inhaler |
| WO2025220834A1 (ko) * | 2024-04-16 | 2025-10-23 | 한미약품 주식회사 | 흡입제 조성물 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356167A (en) * | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
| US4483922A (en) * | 1982-05-14 | 1984-11-20 | Amf Inc. | Inactivation of enzymes |
| US4581020A (en) * | 1983-07-18 | 1986-04-08 | Trimedyne, Inc. | Medication delivery device and system for percutaneous administration of medication |
| US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5693338A (en) | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US6024090A (en) | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
| CN1170409A (zh) | 1994-12-01 | 1998-01-14 | 富山化学工业株式会社 | 新的2,3－二氧代哌嗪衍生物及其盐 |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| EP0941114B1 (en) | 1996-11-12 | 2005-02-23 | Novo Nordisk A/S | Use of glp-1 peptides |
| AU1617399A (en) | 1997-12-05 | 1999-06-28 | Eli Lilly And Company | Glp-1 formulations |
| US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| CA2228182C (en) * | 1998-01-26 | 2007-03-20 | George Volgyesi | Breath-powered mist inhaler |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| CA2367131C (en) | 1999-04-05 | 2007-07-03 | Solomon S. Steiner | Methods for fine powder formation |
| DE60036367T2 (de) | 1999-06-21 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes |
| DK1808438T3 (da) * | 1999-06-29 | 2014-10-27 | Mannkind Corp | Rensning og stabilisering af peptid og proteiner i lægemidler |
| US7464706B2 (en) | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
| US7305986B1 (en) | 1999-07-23 | 2007-12-11 | Mannkind Corporation | Unit dose capsules for use in a dry powder inhaler |
| US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
| US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| BR0111562A (pt) | 2000-06-16 | 2003-04-15 | Lilly Co Eli | Análogos de peptìdeo 1 semelhantes ao glucagon |
| DK1311269T3 (da) | 2000-08-04 | 2012-03-26 | Dmi Biosciences Inc | Fremgangsmåde til anvendelse af diketopiperaziner og sammensætning, som indeholder dem |
| US7259233B2 (en) * | 2000-12-13 | 2007-08-21 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| US7232897B2 (en) | 2001-04-24 | 2007-06-19 | Harvard University, President And Fellows Of Harvard College | Compositions and methods for modulating NH2-terminal Jun Kinase activity |
| EP1542712A2 (en) | 2001-06-01 | 2005-06-22 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| US7101843B2 (en) | 2001-08-23 | 2006-09-05 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| CN1635900A (zh) | 2001-08-28 | 2005-07-06 | 伊莱利利公司 | Glp－1和基础胰岛素的预混合物 |
| US7179788B2 (en) | 2001-10-19 | 2007-02-20 | Eli Lilly And Company | Biphasic mixtures of GLP-1 and insulin |
| SE524990C2 (sv) * | 2002-04-12 | 2004-11-09 | Microdrug Ag | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver |
| AU2003257156B2 (en) * | 2002-08-01 | 2007-08-30 | Mannkind Corporation | Cell transport compositions and uses thereof |
| US20040038865A1 (en) | 2002-08-01 | 2004-02-26 | Mannkind Corporation | Cell transport compositions and uses thereof |
| US11304992B2 (en) * | 2002-08-01 | 2022-04-19 | Mannkind Corporation | Inhalable dry powder pharmaceutical composition |
| US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
| US20040121964A1 (en) | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| CN1732012A (zh) * | 2002-12-27 | 2006-02-08 | 迪奥贝克斯公司 | 用于预防和控制胰岛素诱发的低血糖的组合物和方法 |
| ES2572975T3 (es) * | 2003-05-15 | 2016-06-03 | Ampio Pharmaceuticals, Inc. | Tratamiento de enfermedades mediadas por los linfocitos T |
| US20070027063A1 (en) * | 2004-01-12 | 2007-02-01 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
| PL1786784T3 (pl) | 2004-08-20 | 2011-04-29 | Mannkind Corp | Kataliza syntezy diketopiperazyn |
| KR20070057829A (ko) | 2004-08-23 | 2007-06-07 | 맨카인드 코포레이션 | 포스포디에스테라아제 5형의 억제제의 폐 전달 |
| EP2314298B1 (en) * | 2004-08-23 | 2015-05-27 | MannKind Corporation | Microparticles comprising diketopiperazine salts for drug delivery |
| DE102005033398A1 (de) * | 2004-11-10 | 2006-05-11 | Alfred Von Schuckmann | Inhalier-Gerät |
| SE0402976L (sv) | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
| US20100041612A1 (en) | 2005-09-08 | 2010-02-18 | Martin Beinborn | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof |
| AU2006290870B2 (en) * | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
| WO2007053946A1 (en) * | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
| AU2007221366B2 (en) * | 2006-02-22 | 2012-08-23 | Msd Italia S.R.L. | Oxyntomodulin derivatives |
| DK1986679T3 (da) | 2006-02-22 | 2017-11-20 | Mannkind Corp | Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof |
| KR101438839B1 (ko) | 2006-04-14 | 2014-10-02 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제 |
| US20090098207A1 (en) * | 2007-07-24 | 2009-04-16 | Nexbio, Inc. | Technology for the Preparation of Microparticles |
| WO2009055742A2 (en) * | 2007-10-24 | 2009-04-30 | Mannkind Corporation | Delivery of active agents |
| EP2060268A1 (en) | 2007-11-15 | 2009-05-20 | Novo Nordisk A/S | Pharmaceutical compositions for pulmonary or nasal delivery of peptides |
| US20110034385A1 (en) * | 2008-04-07 | 2011-02-10 | National Institute Of Immunology | Compositions Useful for the Treatment of Diabetes and Other Chronic Disorder |
-
2008
- 2008-10-24 WO PCT/US2008/081221 patent/WO2009055742A2/en not_active Ceased
- 2008-10-24 AU AU2008316636A patent/AU2008316636B2/en active Active
- 2008-10-24 KR KR1020107011092A patent/KR20100090692A/ko not_active Ceased
- 2008-10-24 CA CA2703234A patent/CA2703234C/en active Active
- 2008-10-24 KR KR1020137027813A patent/KR20130123470A/ko not_active Ceased
- 2008-10-24 JP JP2010531299A patent/JP5813323B2/ja active Active
- 2008-10-24 EP EP08840828A patent/EP2214647A2/en not_active Ceased
- 2008-10-24 MX MX2010004508A patent/MX2010004508A/es active IP Right Grant
- 2008-10-24 US US12/258,341 patent/US8372804B2/en active Active
- 2008-10-24 CN CN200880122681.1A patent/CN101969928B/zh active Active
- 2008-10-24 RU RU2010120672/15A patent/RU2467741C2/ru active
- 2008-10-24 BR BRPI0818874 patent/BRPI0818874A2/pt not_active IP Right Cessation
-
2012
- 2012-08-23 RU RU2012136221/15A patent/RU2012136221A/ru not_active Application Discontinuation
-
2013
- 2013-01-09 US US13/737,823 patent/US20130118491A1/en not_active Abandoned
-
2015
- 2015-07-22 JP JP2015145109A patent/JP2015227357A/ja active Pending
-
2019
- 2019-02-04 US US16/267,231 patent/US20190167580A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/741,260 patent/US20200146981A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/864,828 patent/US20220362147A1/en active Pending
-
2024
- 2024-02-06 US US18/434,301 patent/US20240197627A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500851A5 (enExample) | ||
| RU2012136221A (ru) | Доставка активных веществ | |
| AU2018200429B2 (en) | Mast Cell Stabilizers Treatment For Systemic Disorders | |
| JP2011500850A5 (enExample) | ||
| ES2775498T3 (es) | Formulación en polvo nasal para el tratamiento de la hipoglucemia | |
| JP2007520506A5 (enExample) | ||
| JP2004522714A5 (enExample) | ||
| JP2013518124A5 (enExample) | ||
| JP2020536121A5 (enExample) | ||
| JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| JP2019504040A (ja) | 中等度〜重度のインフルエンザの処置 | |
| JP5117230B2 (ja) | ２型糖尿病治療用の併用医薬 | |
| JP2023524064A (ja) | ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 | |
| CN1297272C (zh) | 马来酸氯苯那敏的新用途 | |
| JP2006508993A5 (enExample) | ||
| Roe et al. | Doctor, stop needling me: an update on alternative routes of insulin administration | |
| JP2007091641A (ja) | ２型糖尿病治療用の併用医薬 |